Cumming, David, Song, Fujian, Taylor, Rod S., Zahra, Mehdi, Williams, Adrian and Eggington, Simon (2022) Cost-effectiveness of 4 mg dibotermin alfa/absorbable collagen sponge versus iliac crest bone graft for lumbar degenerative disc disease in the United Kingdom. Journal of Medical Economics, 25 (1). pp. 59-65. ISSN 1369-6998

Preview

PDF (Accepted_Manuscript) - Accepted Version Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (994kB) | Preview

Abstract

Aims: To develop a model to evaluate the cost-effectiveness of 4 mg dibotermin alfa/absorbable collagen sponge (ACS) versus iliac crest bone graft (ICBG) in patients with lumbar degenerative disc disease in the United Kingdom. Materials & methods: A Markov decision-analytic model was constructed to calculate costs and quality-adjusted life-years over a 4-year time horizon in each treatment group, from a United Kingdom National Health Service perspective. An individual patient data meta-analysis was undertaken to synthesize data from four randomized controlled trials and two single-arm studies concerning health-related quality of life and procedural resource use. Current cost data from the United Kingdom were then applied to determine the overall mean cost per patient in each group. One-way and probabilistic sensitivity analyses were undertaken to explore the impact of parameter uncertainty. Results: The model predicted 4-year discounted cost savings of £192 per patient treated with dibotermin alfa/ACS, compared with ICBG, and a gain of 0.0114 QALYs per patient over the same time period. Sensitivity analyses indicated that the results were most sensitive to variability in the differences in health-related quality of life and secondary surgery rate, with dibotermin alfa/ACS having a 60% probability of being cost-effective at a willingness-to-pay threshold of £20,000 per QALY gained. Limitations: There is uncertainty in the difference in cost and QALYs between the two groups. However, comprehensive sensitivity analyses were undertaken to explore this and present the results in a transparent manner. Conclusions: Our results provide an economic case for the use of 4 mg dibotermin alfa/ACS versus iliac crest bone graft, with additional health benefits predicted at reduced overall cost.

Item Type:	Article
Uncontrolled Keywords:	cost-effectiveness,health economics,quality of life,spinal fusion,health policy ,/dk/atira/pure/subjectarea/asjc/2700/2719
Faculty \ School:	Faculty of Medicine and Health Sciences > Norwich Medical School
Related URLs:	http://www.scopus.com/inward/record.url?... https://www.tandfonline.com/doi/full/10....
Depositing User:	LivePure Connector
Date Deposited:	15 Dec 2021 10:30
Last Modified:	07 Jan 2022 09:30
URI:	https://ueaeprints.uea.ac.uk/id/eprint/82693
DOI:	10.1080/13696998.2021.2017200

Actions (login required)

View Item